These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23007442)

  • 1. Population effects and variability.
    Dorne JL; Amzal B; Bois F; Crépet A; Tressou J; Verger P
    Methods Mol Biol; 2012; 929():521-81. PubMed ID: 23007442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism, variability and risk assessment.
    Dorne JL
    Toxicology; 2010 Feb; 268(3):156-64. PubMed ID: 19932147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.
    Dorne JL
    Fundam Clin Pharmacol; 2004 Dec; 18(6):609-20. PubMed ID: 15548231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The refinement of uncertainty/safety factors in risk assessment by the incorporation of data on toxicokinetic variability in humans.
    Dorne JL; Renwick AG
    Toxicol Sci; 2005 Jul; 86(1):20-6. PubMed ID: 15800035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review.
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2005 Feb; 43(2):203-16. PubMed ID: 15621332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision of estimates of an ADI (or TDI or PTWI).
    Speijers GJ
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S87-93. PubMed ID: 10597619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human variability in hepatic and renal elimination: implications for risk assessment.
    Dorne JL
    J Appl Toxicol; 2007; 27(5):411-20. PubMed ID: 17497760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment.
    Judson RS; Kavlock RJ; Setzer RW; Hubal EA; Martin MT; Knudsen TB; Houck KA; Thomas RS; Wetmore BA; Dix DJ
    Chem Res Toxicol; 2011 Apr; 24(4):451-62. PubMed ID: 21384849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shellfish and residual chemical contaminants: hazards, monitoring, and health risk assessment along French coasts.
    Guéguen M; Amiard JC; Arnich N; Badot PM; Claisse D; Guérin T; Vernoux JP
    Rev Environ Contam Toxicol; 2011; 213():55-111. PubMed ID: 21541848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A lifestage-specific approach to hazard and dose-response characterization for children's health risk assessment.
    Makris SL; Thompson CM; Euling SY; Selevan SG; Sonawane B
    Birth Defects Res B Dev Reprod Toxicol; 2008 Dec; 83(6):530-46. PubMed ID: 19085945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human biomonitoring as a pragmatic tool to support health risk management of chemicals--examples under the EU REACH programme.
    Boogaard PJ; Hays SM; Aylward LL
    Regul Toxicol Pharmacol; 2011 Feb; 59(1):125-32. PubMed ID: 20933039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards quantitative uncertainty assessment for cancer risks: central estimates and probability distributions of risk in dose-response modeling.
    Kopylev L; Chen C; White P
    Regul Toxicol Pharmacol; 2007 Dec; 49(3):203-7. PubMed ID: 17905499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancing exposure characterization for chemical evaluation and risk assessment.
    Cohen Hubal EA; Richard A; Aylward L; Edwards S; Gallagher J; Goldsmith MR; Isukapalli S; Tornero-Velez R; Weber E; Kavlock R
    J Toxicol Environ Health B Crit Rev; 2010 Feb; 13(2-4):299-313. PubMed ID: 20574904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The benchmark dose method--review of available models, and recommendations for application in health risk assessment.
    Filipsson AF; Sand S; Nilsson J; Victorin K
    Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
    Clewell HJ; Gentry PR; Gearhart JM
    J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of the U.S. Army's health risk assessments for oral exposure to six chemical-warfare agents. Introduction.
    J Toxicol Environ Health A; 2000 Mar; 59(5-6):281-526. PubMed ID: 10742829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uncertainty and variability in human exposure limits - a chemical-specific approach for ciprofloxacin and methotrexate.
    Oldenkamp R; Huijbregts MA; Ragas AM
    Crit Rev Toxicol; 2016; 46(3):261-78. PubMed ID: 26648512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical risk assessment and uncertainty associated with extrapolation across exposure duration.
    Pohl HR; Chou CH; Ruiz P; Holler JS
    Regul Toxicol Pharmacol; 2010 Jun; 57(1):18-23. PubMed ID: 19944126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.